trandolapril ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 2712 87679-37-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • trandolapril
  • gopten
  • mavik
  • odrik
The effect of trandolapril in hypertension appears to result primarily from the inhibition of circulating and tissue ACE activity thereby reducing angiotensin II formation, decreasing vasoconstriction, decreasing aldosterone secretion, and increasing plasma renin. Decreased aldosterone secretion leads to diuresis, natriuresis, and a small increase of serum potassium. Trandolapril is deesterified to the diacid metabolite, trandolaprilat, which is approximately eight times more active as an inhibitor of ACE activity.
  • Molecular weight: 430.55
  • Formula: C24H34N2O5
  • CLOGP: 2.10
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 95.94
  • ALOGS: -4.32
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.06 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 10 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.25 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.17 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.26 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 26, 1996 FDA ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 58.60 20.22 31 2755 33324 50569014
Paranoia 55.40 20.22 21 2765 10327 50592011
Psychotic disorder 52.20 20.22 25 2761 21787 50580551
Hallucination, auditory 51.11 20.22 20 2766 10708 50591630
Focal segmental glomerulosclerosis 44.14 20.22 11 2775 1330 50601008
Cerebellar haematoma 39.93 20.22 8 2778 357 50601981
Endometrial ablation 38.26 20.22 9 2777 854 50601484
Red blood cells urine positive 36.22 20.22 11 2775 2764 50599574
White blood cells urine positive 30.81 20.22 11 2775 4567 50597771
Bacterial test 30.74 20.22 8 2778 1149 50601189
Vaginal discharge 29.36 20.22 11 2775 5229 50597109
Hyperaesthesia 27.88 20.22 12 2774 8161 50594177
Urine abnormality 27.50 20.22 11 2775 6227 50596111
Acute kidney injury 25.19 20.22 45 2741 228013 50374325
Cardiogenic shock 23.21 20.22 13 2773 15586 50586752
Organising pneumonia 23.08 20.22 9 2777 4765 50597573
Dorsal ramus syndrome 21.54 20.22 4 2782 119 50602219
Palindromic rheumatism 21.31 20.22 4 2782 126 50602212
Angioedema 20.88 20.22 17 2769 37659 50564679

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Oesophageal obstruction 77.44 18.89 16 3271 405 29570835
Bezoar 66.84 18.89 16 3271 803 29570437
Arterial disorder 38.61 18.89 11 3276 1092 29570148
Oesophageal haemorrhage 29.41 18.89 9 3278 1144 29570096
Reading disorder 27.52 18.89 7 3280 451 29570789
Jugular vein distension 25.37 18.89 7 3280 618 29570622
Waist circumference increased 24.09 18.89 7 3280 745 29570495
Body mass index increased 23.39 18.89 7 3280 825 29570415
Bronchial wall thickening 21.77 18.89 7 3280 1045 29570195
Eosinophil count increased 21.05 18.89 12 3275 7357 29563883
Dysgraphia 20.75 18.89 8 3279 2030 29569210
Hypopnoea 20.56 18.89 7 3280 1247 29569993
Wrong product administered 20.40 18.89 10 3277 4521 29566719
Lung opacity 19.85 18.89 7 3280 1385 29569855
Cough 19.21 18.89 43 3244 126684 29444556
Hypotension 19.13 18.89 56 3231 194298 29376942
Chest X-ray abnormal 18.98 18.89 9 3278 3785 29567455

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Oesophageal obstruction 71.12 17.88 16 5458 803 64492455
Lactic acidosis 59.54 17.88 46 5428 61364 64431894
Bezoar 55.40 17.88 16 5458 2187 64491071
Reading disorder 39.84 17.88 10 5464 803 64492455
Paranoia 37.48 17.88 21 5453 16331 64476927
Arterial disorder 36.18 17.88 11 5463 1794 64491464
Endometrial ablation 35.05 17.88 9 5465 792 64492466
Hallucination, auditory 34.12 17.88 20 5454 16919 64476339
Cerebellar haematoma 32.58 17.88 8 5466 587 64492671
Hyperkalaemia 31.80 17.88 41 5433 101088 64392170
Psychotic disorder 31.54 17.88 25 5449 34553 64458705
Acute kidney injury 31.09 17.88 96 5378 449144 64044114
Oesophageal haemorrhage 28.98 17.88 9 5465 1575 64491683
Vaginal discharge 27.62 17.88 11 5463 3986 64489272
Bacterial test 26.97 17.88 8 5466 1199 64492059
Red blood cells urine positive 26.41 17.88 11 5463 4467 64488791
Hypoglycaemia 26.02 17.88 35 5439 89857 64403401
Dysgraphia 25.55 17.88 10 5464 3461 64489797
White blood cells urine positive 24.43 17.88 11 5463 5387 64487871
Cardiogenic shock 22.45 17.88 20 5454 32407 64460851
Jugular vein distension 22.05 17.88 7 5467 1315 64491943
Waist circumference increased 21.80 17.88 7 5467 1364 64491894
Urine abnormality 21.19 17.88 11 5463 7351 64485907
Body mass index increased 20.83 17.88 7 5467 1572 64491686
Bronchial wall thickening 19.54 17.88 7 5467 1900 64491358
Cough 19.40 17.88 63 5411 302085 64191173
Libido decreased 19.30 17.88 9 5465 4775 64488483
Coagulopathy 18.82 17.88 18 5456 31902 64461356
Rales 18.31 17.88 13 5461 15216 64478042
Hyperaesthesia 18.03 17.88 11 5463 10003 64483255
Combined pulmonary fibrosis and emphysema 18.03 17.88 3 5471 29 64493229

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA10 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BB10 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
FDA MoA N0000000181 Angiotensin-converting Enzyme Inhibitors
FDA EPC N0000175562 Angiotensin Converting Enzyme Inhibitor
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
CHEBI has role CHEBI:35457 ACE inhibitor
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:50266 Prodrugs
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:76967 human xenobiotic metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure indication 48447003
Left ventricular cardiac dysfunction indication 429589006
Atrial fibrillation off-label use 49436004 DOID:0060224
Diabetic renal disease off-label use 127013003
Diastolic heart failure off-label use 418304008 DOID:9775
Nondiabetic Proteinuric Nephropathy off-label use
Hyperkalemia contraindication 14140009
Ventricular tachycardia contraindication 25569003
Complete atrioventricular block contraindication 27885002
Acute cerebrovascular insufficiency contraindication 29322000
Sick sinus syndrome contraindication 36083008 DOID:13884
Immunosuppression contraindication 38013005
Angioedema contraindication 41291007 DOID:1558
Low cardiac output syndrome contraindication 44088000
Low blood pressure contraindication 45007003
Bradycardia contraindication 48867003
Lown-Ganong-Levine syndrome contraindication 55475008 DOID:13087
Aortic valve stenosis contraindication 60573004 DOID:1712
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Duchenne muscular dystrophy contraindication 76670001 DOID:11723
Transplantation contraindication 77465005
Chronic idiopathic constipation contraindication 82934008
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of connective tissue contraindication 105969002 DOID:65
Liver function tests abnormal contraindication 166603001
Second degree atrioventricular block contraindication 195042002
Hypertrophic cardiomyopathy contraindication 233873004 DOID:11984
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Neuromuscular Transmission Deficiency contraindication
Hemodialysis with High-Flux Membrane contraindication
First Degree Atrioventricular Heart Block contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.23 acidic
pKa2 5.77 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 8.12 WOMBAT-PK CHEMBL

External reference:

IDSource
4020971 VUID
N0000148444 NUI
D00383 KEGG_DRUG
4020971 VANDF
C0076891 UMLSCUI
CHEBI:9649 CHEBI
CHEBI:141521 CHEBI
X93 PDB_CHEM_ID
CHEMBL1519 ChEMBL_ID
DB00519 DRUGBANK_ID
C052035 MESH_SUPPLEMENTAL_RECORD_UI
5484727 PUBCHEM_CID
6453 IUPHAR_LIGAND_ID
C061095 MESH_SUPPLEMENTAL_RECORD_UI
6455 IUPHAR_LIGAND_ID
5746 INN_ID
87679-71-8 SECONDARY_CAS_RN
1T0N3G9CRC UNII
5464097 PUBCHEM_CID
DB14209 DRUGBANK_ID
1546379 RXNORM
107488 MMSL
5448 MMSL
5606 MMSL
5642 MMSL
d04008 MMSL
004452 NDDF
108562001 SNOMEDCT_US
386871006 SNOMEDCT_US
C0165477 UMLSCUI
CHEMBL1201387 ChEMBL_ID
6370 INN_ID
RR6866VL0O UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 42806-052 TABLET 1 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 42806-053 TABLET 2 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 42806-054 TABLET 4 mg ORAL ANDA 18 sections
Trandolapril Human Prescription Drug Label 1 50090-4120 TABLET 2 mg ORAL ANDA 21 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 50090-4128 TABLET 1 mg ORAL ANDA 19 sections
Mavik HUMAN PRESCRIPTION DRUG LABEL 1 54868-5099 TABLET 4 mg ORAL NDA 20 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 54868-5311 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL NDA 20 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 54868-5320 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL NDA 20 sections
Tarka HUMAN PRESCRIPTION DRUG LABEL 2 54868-5548 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL NDA 20 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 54868-6061 TABLET 4 mg ORAL ANDA 14 sections
Trandolapril Human Prescription Drug Label 1 57237-089 TABLET 1 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 57237-090 TABLET 2 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 57237-091 TABLET 4 mg ORAL ANDA 20 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 63629-8003 TABLET 2 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 63629-8390 TABLET 4 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 65862-164 TABLET 1 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 65862-165 TABLET 2 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 65862-166 TABLET 4 mg ORAL ANDA 20 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68151-0757 TABLET 1 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68180-566 TABLET 1 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68180-567 TABLET 2 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68180-568 TABLET 4 mg ORAL ANDA 18 sections
Trandolapril HUMAN PRESCRIPTION DRUG LABEL 1 68258-6100 TABLET 4 mg ORAL ANDA 20 sections
Trandolapril and Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 68462-294 TABLET, FILM COATED, EXTENDED RELEASE 1 mg ORAL ANDA 20 sections
Trandolapril and Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 68462-295 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL ANDA 20 sections
Trandolapril and Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 68462-296 TABLET, FILM COATED, EXTENDED RELEASE 2 mg ORAL ANDA 20 sections
Trandolapril and Verapamil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 68462-329 TABLET, FILM COATED, EXTENDED RELEASE 4 mg ORAL ANDA 20 sections
Trandolapril Human Prescription Drug Label 1 71335-1431 TABLET 2 mg ORAL ANDA 20 sections